'A beautiful soul': Funeral held for baby boy killed in wrong-way crash on Highway 401
A funeral was held on Wednesday for a three-month-old boy who died after being involved in a wrong-way crash on Highway 401 in Whitby last week.
An experimental Alzheimer's drug modestly slowed the brain disease's inevitable worsening -- but the anxiously awaited new data leaves unclear how much difference that might make in people's lives.
Japanese drugmaker Eisai and its U.S. partner Biogen had announced earlier this fall that the drug lecanemab appeared to work, a badly needed bright spot after repeated disappointments in the quest for better treatments of the incurable disease.
Late Tuesday, the companies provided full results of the study of nearly 1,800 people in early stages of the mind-robbing disease. The data was presented at an Alzheimer's meeting in San Francisco and published in The New England Journal of Medicine.
Lecanemab delayed patients' worsening by about five months over the course of the 18-month study, Eisai's Dr. Michael Irizarry told The Associated Press. Also, lecanemab recipients were 31 per cent less likely to advance to the next stage of the disease during the study.
"That translates to more time in earlier stages" when people function better, Irizarry said.
Every two weeks, study participants received intravenous lecanemab or a dummy infusion. Researchers tracked them using an 18-point scale that measures cognitive and functional ability.
The study's key finding: Those given lecanemab declined more slowly, a difference of not quite half a point on that scale over the 18 months, concluded the research team led by Dr. Christopher van Dyck at Yale University.
Doctors are divided over how much difference that may make for patients and families -- especially as the drug carries some worrying potential safety risks including brain swelling.
"It is unlikely that the small difference reported in this trial will be noticeable by individual patients," said Dr. Madhav Thambisetty of the National Institute on Aging, who noted he wasn't speaking for the government agency.
He said many researchers believe a meaningful improvement would require at least a difference of a full point on that 18-point scale.
But Dr. Ron Petersen, an Alzheimer's expert at the Mayo Clinic, said the drug's effect was "a modest one but I think it's clinically meaningful" -- because even a few months' delay in progression could give someone a little more time when they're functioning independently.
The trial is important because it shows a drug that attacks a sticky protein called amyloid -- considered one of several culprits behind Alzheimer's -- can delay disease progression, said Maria Carrillo, chief science officer for the Alzheimer's Association.
"We all understand that this is not a cure and we're all trying to really grasp what it means to slow Alzheimer's, because this is a first," Carrillo said.
But any delay in cognitive decline early on could be meaningful for "how much time we have with our loved ones in a stage of disease where we can still enjoy family and outings, vacations, bucket lists," she said.
Amyloid-targeting drugs can cause side effects that include swelling and bleeding in the brain, and lecanemab did as well. One type of this swelling was seen in about 13% of recipients. Eisai said most were mild or asymptomatic.
Also, two deaths have been publicly reported among lecanemab users who also were taking blood-thinning medications for other health problems. Eisai said Tuesday the deaths can't be attributed to the Alzheimer's drug.
But Mayo's Petersen said if lecanemab is approved for use in the U.S., he'd avoid prescribing it to people on blood thinners at least initially.
And Thambisetty said the death reports raise concern about how the drug may be tolerated outside of research studies "where patients are likely to be sicker and have multiple other medical conditions."
The Food and Drug Administration is considering approving lecanemab under its fast-track program, with a decision expected in early January. If approved, it would be the second anti-amyloid drug on the market.
Nearly all treatments available for the 6 million Americans with Alzheimer's -- and millions more worldwide with the most common form of dementia -- only temporarily ease symptoms. Scientists don't yet know exactly how Alzheimer's forms but one theory is that gunky amyloid buildup plays a key role, although drug after drug that targets it has failed.
In a contentious move last year, the FDA approved the first amyloid-targeting drug, Biogen's Aduhelm, despite lack of evidence of better patient outcomes. Insurers and many doctors have hesitated to prescribe the pricey drug -- another reason experts have anxiously awaited word of how well the newer lecanemab may work.
If the FDA approves lecanemab, patients and their families will need a voice in deciding whether it's worth the hassle of IV infusions and the risk of side effects for the chance of at least some delay in progression, Petersen said.
"I don't think we're going to stop the disease in its tracks" with just amyloid-targeting drugs, he added, saying it will take a combination of medications that target additional Alzheimer's culprits.
Researchers are preparing to test lecanemab with other experimental drugs, and how it works in high-risk people before they show the first signs of memory problems.
------------
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education. The AP is solely responsible for all content.
A funeral was held on Wednesday for a three-month-old boy who died after being involved in a wrong-way crash on Highway 401 in Whitby last week.
Toronto police say a man was taken into custody outside Drake's Bridle Path mansion Wednesday afternoon after he tried to gain access to the residence.
U.S. President Joe Biden said for the first time Wednesday he would halt shipments of American weapons to Israel, which he acknowledged have been used to kill civilians in Gaza, if Prime Minister Benjamin Netanyahu orders a major invasion of the city of Rafah.
Independent U.S. presidential candidate Robert F. Kennedy Jr. had a parasite in his brain more than a decade ago, but has fully recovered, his campaign said, after the New York Times reported about the ailment.
There is currently a whooping cough epidemic in Europe, with 10 times as many cases compared to the previous two years. While an outbreak has not been declared nationwide in Canada, whooping cough is regularly detected in the country.
Pfizer has agreed to settle more than 10,000 lawsuits about cancer risks related to the now discontinued heartburn drug Zantac, Bloomberg News reported on Wednesday, citing people familiar with the deal.
Quebec Premier Francois Legault is defending his comments about a new history museum after he was accused by a prominent First Nations group of trying to erase their history.
British Columbia's human rights tribunal has awarded a neurodigergent actor, who was diagnosed with sensory and learning disorders, more than $55,000 after finding that a Kelowna theatre company discriminated against him because of his disabilities.
It's not quite clear who is supposed to be regulating so-called sovereign cannabis stores or even ensure they're benefiting Indigenous communities.
The stakes have been set for a bet between Vancouver and Edmonton's mayors on who will win Round 2 of the Stanley Cup playoffs.
A grieving mother is hosting a helmet drive in the hopes of protecting children on Manitoba First Nations from a similar tragedy that killed her daughter.
A chicken farmer near Mattawa made an 'eggstraordinary' find Friday morning when she discovered one of her hens laid an egg close to three times the size of an average large chicken egg.
A P.E.I. lighthouse and a New Brunswick river are being honoured in a Canada Post series.
An Ontario man says he paid more than $7,700 for a luxury villa he found on a popular travel website -- but the listing was fake.
Whether passionate about Poirot or hungry for Holmes, Winnipeg mystery obsessives have had a local haunt for over 30 years in which to search out their latest page-turners.
Eighty-two-year-old Susan Neufeldt and 90-year-old Ulrich Richter are no spring chickens, but their love blossomed over the weekend with their wedding at Pine View Manor just outside of Rosthern.
Alberta Ballet's double-bill production of 'Der Wolf' and 'The Rite of Spring' marks not only its final show of the season, but the last production for twin sisters Alexandra and Jennifer Gibson.
A mother goose and her goslings caused a bit of a traffic jam on a busy stretch of the Trans-Canada Highway near Vancouver Saturday.